Induction of γ-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocumarin derivatives

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 810-825

  Viola, Giampietro ^a   Vedaldi, Daniela ^a   Dall'Acqua, Francesco ^a   Fortunato, Elena ^a   Basso, Giuseppe ^a   Bianchi, Nicoletta ^b   Zuccato, Cristina ^b   Borgatti, Monica ^b   Lampronti, Ilaria ^b   Gambari, Roberto ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Section of Molecular Biology   (Italy)

^c Biotechnology Center   (Italy)

Author keywords

Apoptosis; Cell cycle; Erythroid differentiation; Erythroid precursor; K562 cells; Psoralens

Indexed keywords

CASPASE; FUROCOUMARIN; GLOBIN MESSENGER RNA; PSORALEN DERIVATIVE;

APOPTOSIS; ARTICLE; BETA THALASSEMIA; BLOOD; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LINE; CELL STRAIN K 562; DRUG STRUCTURE; ENZYME ACTIVATION; ERYTHROID CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGHT; LIQUID CULTURE; MITOCHONDRION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SICKLE CELL ANEMIA; STEM CELL; ULTRAVIOLET A RADIATION;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; DNA DAMAGE; ERYTHROID CELLS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLOBINS; HUMANS; K562 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PHOSPHATIDYLSERINES; PSORALENS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ULTRAVIOLET RAYS;

EID: 38649102191     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.007     Document Type: Article

References (59)

1. Olivieri N.F., Rees D.C., Ginder D.G., Thein S.L., Waye J.S., Chang L., et al. Elimination of transfusion through induction of fetal hemoglobin synthesis in Cooley's anemia. Ann NY Acad Sci USA 850 (1998) 100-109
2. Gambari R., and Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. Curr Med Chem 14 (2007) 199-212
3. Fibach E., Bianchi N., Borgatti M., Zuccato C., Finotti A., Lampronti I., et al. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol 77 (2006) 437-441
4. Mischiati C., Sereni A., Lampronti I., Bianchi N., Borgatti M., Prus E., et al. Rapamycin-mediated induction of γ-globin mRNA accumulation in human erythroid cells. Br J Haematol 126 (2004) 612-621
5. Rodgers G.P., and Rachmilewitz E.A. Novel treatment options in the severe beta-globin disorder. Br J Haematol 91 (1995) 263-268
6. Bianchi N., Osti F., Rutigliano C., Ginanni Corradini F., Borsetti E., Tomassetti M., et al. The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells. Br J Haematol 104 (1999) 258-263
7. Bianchi N., Chiarabelli C., Borgatti M., Mischiati C., Fibach E., and Gambari R. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukemia K562 cells with tallimustine. Br J Haematol 113 (2001) 951-961
8. Fibach E., Bianchi N., Borgatti M., Prus E., and Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood 102 (2003) 1276-1281
9. Dall'Acqua F., Viola G., and Vedaldi D. Molecular basis of psoralen photochemotherapy. In: Hoorspool W.M., and Lenci F. (Eds). CRC Handbook of Organic Photochemistry and Photobiology (2004), CRC Press, Boca Raton, USA 1-17 (Chapter 142)
10. Bohr V., and Nielsen P.E. Psoralen-DNA cross link repair in human lymphocytes. Comparison of alkaline elution with electron microscopy. Biochim Biophys Acta 783 (1984) 183-186
11. Bordin F., Dall'Acqua F., and Guiotto A. Angelicins, angular analogs of psoralens: chemistry, photochemical, photobiological and photochemotherapeutic properties. Pharmacol Therapeut 52 (1991) 331-363
12. Duvic M., Chiao N., and Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg 47 (2003) 1449-1554
13. Dall'Amico R., and Messina C. Extracorporeal photochemotherapy for the treatment of graft versus host disease. Ther Apheresis 6 (2002) 296-304
14. Barr M.L., Meiser B.M., Eisen H.J., Roberts R.F., Livi U., Dall'Amico R., et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis transplantation study group. N Engl J Med 339 (1998) 1744-1751
15. Child F.J., Ratnavel R., Watkins P., Samson D., Apperley J., Ball J., et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft versus-host disease (GHVD). Bone Marrow Transplant 23 (1999) 881-887
16. Lampronti I., Bianchi N., Borgatti M., Fibach E., Prus E., and Gambari R. Accumulation of γ-globin mRNA in human erythroid cells treated with angelicin. Eur J Haematol 71 (2003) 189-195
17. Viola G., Fortunato E., Cecconet L., and Basso G. Caspase and mitochondrial dysfunction dependent mechanism of induced apoptosis by photoexcited psoralen derivatives in human lymphocytes. Toxicol In Vitro 21 (2007) 211-216
18. Lozzio C.B., and Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia-chromosome. Blood 45 (1975) 321-334
19. Mahadi T., Alcalay D., Brizard A., Bois M., Millet C., Kitzis A., et al. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation. Biol Cell 90 (1998) 615-627
20. Vedaldi D., Caffieri S., Dall'Acqua F., Andreassi L., Bovalini L., and Martelli P. Khellin, a naturally occurring furochromone, used for the photochemotherapy of skin disease: mechanism of action. Il Farmaco 4 (1988) 333-346
21. Czyz M., Szulawska A., Bednarek A.K., and Düchler M. Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation. Biochem Pharm 70 (2005) 1431-1442
22. Jacquel A., Herrant M., Legros L., Belhacene N., Luciano F., Pages G., et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl K562 cell line and its differentiation towards the erythroid lineage. FASEB J 17 (2003) 2160-2173
23. Bianchi N., Ongaro F., Chiarabelli C., Gualandi L., Mischiati C., Bergamini P., et al. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem Pharmacol 60 (2000) 31-40
24. Hasinoff B.B., Abram M.E., Barnabé B., Khélifa T., Allan W.P., and Yalowich J.C. The catalytic DNA topoisomerase II inhibitor Dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cell line. Mol Pharmacol 59 (2001) 453-461
25. Vermes I., Haanen C., Steffens-Nakken H., and Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Method 184 (1995) 39-51
26. Martin S.J., Reutelingsperger C.P., McGahon A.J., Rader J.A., van Schie R.C., Laface D.M., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182 (1995) 1545-1556
27. m) in apoptosis: an update. Apoptosis 3 (2003) 115-128
28. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
29. Salvioli S., Ardizzoni A., Franceschi C., and Cossarizza A. JC-1 but not DiOC6(3) or rhodamine 123 is a reliable fluorescent probe to asses ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 411 (1997) 77-82
30. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 182 (1995) 367-377
31. Rothe G., and Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescein. J Leukoc Biol 47 (1990) 440-448
32. Petit J.M., Maftah A., Ratinaud M.H., and Julien R. 10N-Nonyl acridine orange interacts with cardiolipin and allows the quantification of this phospholipid in isolated mitochondria. Eur J Biochem 209 (1992) 67-273
33. Gallet P.F., Maftah A., Petit J.M., Denis-Gay M., and Julien R. Direct cardiolipin assay in yeast using the red fluorescence emission of 10-N-nonyl acridine orange. Eur J Biochem 228 (1995) 113-119
34. Kumar S. Caspase function in programmed cell death. Cell Death Differ 14 (2007) 32-43
35. Porter A.G., and Janicke R.U. Emerging role of caspase-3 in apoptosis. Cell Death Differ 6 (1999) 99-104
36. Canman C.E., Lin D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., et al. Activation of the ATM kinase by ionising radiation and phosphorylation by ionising radiations and phosphorylation of p53. Science 281 (1998) 1677-1679
37. Banin S., Mojal L., Scieh S.Y., Taya Y., Andersen C.W., Chessa L., et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 (1998) 1674-1677
38. Sarkaria J.N., Tibbets R.S., Busby E.C., Tibbets R.S., Roos P., Taya Y., et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent caffeine. Cancer Res 59 (1999) 4375-4382
39. Hall-Jackson C.A., Cross D.A., Morrice N., and Smythe C. ATR is a caffeine sensitive DNA activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 18 (1999) 6707-6713
40. Sarkaria J.N., Tibbets R.S., Busby E.C., Kennedy A.P., Hill D.E., and Abraham R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58 (1998) 4375-4382
41. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff H.J., et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297 (2002) 259-263
42. Suto M.J., Turner W.R., Arundel-Suto C.M., Werbel L.M., and Sebolt-Leopold J.S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des 6 (1991) 107-117
43. Zuccato C., Bianchi N., Borgatti M., Lampronti I., Massei F., Favre C., et al. Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells. Acta Haematol 117 (2007) 168-176
44. Viola G., Facciolo L., Vedaldi D., Disarò S., Basso G., and Dall'Acqua F. Differential response of linear and angular psoralen in PUVA-induced apoptosis in HL-60 cells. Photochem Photobiol Sci 3 (2004) 237-239
45. Takagaki K., Katsuma S., Kaminishi Y., Horio T., Tanaka T., Ohgi T., et al. Role of Chk1 and Chk2 in Ara-C induced differentiation of human leukemia K562 cells. Genes Cells 10 (2005) 97-106
46. Canton M., Caffieri S., Dall'Acqua F., and Di Lisa F. PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. FEBS Lett 522 (2002) 168-172
47. Rivella S., May C., Chadburn A., Riviere I., and Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 101 (2003) 2932-2939
48. Paszty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr Opin Hematol 4 (1997) 88-93
49. Beuzard Y. Transgenic mouse models of sickle cell disease. Curr Opin Hematol 3 (1996) 150-155
50. Paszty C., Brion C.M., Manci E., Witkowska H.E., Stevens M.E., Mohandas N., et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278 (1997) 876-878
51. Ryan T.M., Ciavatta D.J., and Townes T.M. Knockout-transgenic mouse model of sickle cell disease. Science 278 (1997) 873-876
52. Sauvage C., Rouyer-Fessard P., and Beuzard Y. Improvement of mouse beta thalassaemia by hydroxyurea. Br J Haematol 84 (1993) 492-496
53. De Franceschi L., Rouyer-Fessard P., Alper S.L., Jouault H., Brugnara C., and Beuzard Y. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy. Blood 87 (1996) 1188-1195
54. Iyamu W.E., Lian L., and Asakura T. Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice. Chemotherapy 47 (2001) 270-278
55. Iyamu E.W., Turner E.A., and Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol 122 (2003) 1001-1008
56. Jamsai D., Zaibak F., Khongnium W., Vadolas J., Voullaire L., Fowler K.J., et al. A humanized mouse model for a common beta0-thalassemia mutation. Genomics 85 (2005) 453-461
57. Vadolas J., Nefedov M., Wardan H., Mansooriderakshan S., Voullaire L., Jamsai D., et al. Humanized beta-thalassemia mouse model containing the common IVSI-110 splicing mutation. J Biol Chem 281 (2006) 7399-7405
58. Liu X.L., Yuan J.Y., Zhang J.W., Zhang X.H., and Wang R.X. Differential gene expression in human hematopoietic stem cells specified toward erythroid, megakaryocytic, and granulocytic lineage. J Leukoc Biol 82 (2007) 986-1002
59. Hankins J.S., Helton K.J., McCarville M.B., Li C.S., Wang W.C., and Ware R.E. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 50 (2007) 293-297